144 results about "Peptide antigen" patented technology

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The present disclosure provides compositions and methods for targeting neoantigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors, that bind to the neoantigen: HLA complex. The binding protein further comprises a construct comprising a fusion protein of the CD95 extracellular domain and the CD137 intracellular signaling domain (Fas-41BB), and a CDS coreceptor alpha or beta chain. The disclosed binding proteins are highly sensitive to antigens and are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure (i) have no alloreactivity, substantially no alloreactivity, and / or low risk of alloreactivity, to amino acid sequences from human proteomes and / or (ii) to human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

The invention discloses a carbamylated polypeptide and application thereof in preparation of a rheumatoid arthritis diagnostic kit. The invention provides a cyclization carbamylation polypeptide as shown in SEQ ID NO. 1 and SEQ ID NO. 2 or a combination of the cyclization carbamylation polypeptide and the combination of the cyclization carbamylation polypeptide and the combination. Tests prove that the cyclized carbamylation polypeptide antigens as shown in SEQ ID NO.1 and SEQ ID NO.2 independently have high diagnostic value for diagnosing the negative RA of the anti-cyclic citrullinated peptide antibody, and respectively have application prospects of being developed into diagnostic kits for the negative RA of the anti-cyclic citrullinated peptide antibody; the combination of SEQ ID NO.1 and SEQ ID NO.2 further improves the diagnosis value of the anti-cyclic citrullinated peptide protein antibody negative RA, and has the application prospect of being developed into the anti-cyclic citrullinated peptide protein antibody negative RA diagnosis kit in a combined manner.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

The invention relates to application of RNAP III specific polypeptide antigen in a kit for detecting systemic sclerosis, belongs to the technical field of biotechnology detection, and solves at least one of the problems of low detection specificity, low positive rate and the like of the existing kit in the prior art. The RNAP III specific polypeptide antigen comprises polypeptides with the amino acid sequences as shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3. The RNAP III specific polypeptide antigen can be used for detecting the RNAP III. The RNAP III specific polypeptide antigen has good application value in detecting serum diagnosis of systemic sclerosis patients, the RNAP III specific polypeptide antigen is high in purity and can reach 95% or above, the impurity content is low, the antigen specificity is high, the detection result is stable, the detection specificity is improved, the specificity is close to 100%, and the application value of the RNAP III specific polypeptide antigen is greatly improved. And the production cost of the RNAP III specific polypeptide provided by the invention is low.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

Disclosed herein are protein-based compositions and conjugates thereof that can take advantage of beneficial delivery properties to improve vaccine efficacy. An example protein-based composition includes an albumin-binding nanobody and a peptide antigen domain. An example conjugate includes the protein-based composition attached to a drug through a linker. Also disclosed are methods of making and using the protein-based compositions and conjugates thereof.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The embodiment of the invention provides a polypeptide antigen as well as a preparation method and application thereof. The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg, and the amino acid sequence of the polypeptide antigen is as shown in the specification. The polypeptide antigen has high conformational stability, by arranging a diphenyl cyclooctyne group (DBCO) on a side chain of a Lys residue in the polypeptide antigen and through group modification, the activity of carrying out a click chemical reaction with an endogenous or exogenous azide of a biological system is provided, and the circulation half-life period of polypeptide in a body is remarkably prolonged; through an annular structure and group modification, the polypeptide antigen can effectively target and act on T cells, and the treatment efficiency is improved.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

A carrier system includes a nanocarrier and a peptide non-covalently bound to the nanocarrier. The peptide comprises an adaptor peptide sequence fused to the N-terminus of the target peptide, the adaptor peptide sequence being designed to facilitate binding to the nanocarrier. Also disclosed is a method of improving the immunogenicity of a peptide antigen by fusing the peptide antigen with an adaptor peptide sequence to form an immune peptide and contacting the immune peptide with a compatible nanocarrier. Further, a method of treating disease by immunizing with a peptide of interest that has been fused to an adaptor peptide sequence and thus bound to a nanocarrier is provided. The method induces an immune response to the peptide of interest to treat cancer, viral infection, bacterial infection, parasitic infection, autoimmunity, or an adverse immune response to a biological agent.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

To provide peptide-based vaccines for inducing immune response and production methods and uses thereof.SOLUTION: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject. The present inventors have developed novel compositions and methods of manufacturing peptide-based vaccines that overcome at least one of the limitations of current peptide-based vaccine approaches. The novel peptide-based vaccine compositions and methods of manufacturing disclosed herein account for the variability in the physical and chemical properties of peptide antigens and are therefore generalizable for any peptide antigen.SELECTED DRAWING: None

The present invention relates to an application of an RNAP III specific polypeptide antigen in a kit for detecting systemic sclerosis, belonging to the field of biotechnology detection technology, and solving at least one of the problems of low detection specificity and low positive rate of existing kits in the prior art. The RNAP III specific polypeptide antigen includes polypeptides with amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3. The RNAP III specific polypeptide antigen of the present invention has good application value in the detection of serum diagnosis of systemic sclerosis patients, because the purity of the RNAP III specific polypeptide antigen is high, which can reach more than 95%, the impurity content is small, the antigen specificity is strong, the result is stable in the detection, the specificity of the detection is improved, and the specificity is close to 100%, and the production cost of the RNAP III specific polypeptide of the present invention is low.

The present disclosure provides compositions and methods for targeting Ras antigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors that bind to the Ras antigen: HLA complex. The disclosed binding proteins are highly sensitive to antigens, which binding proteins are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure are non-alloreactive, substantially non-alloreactive, and / or alloreactivity with a lower risk against (i) amino acid sequences from human proteomes and / or (ii) human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

A method for measuring kinetics of Ca2+ flux in differentially responding T cells that form monolayer on the glass surface in response to antigenic peptides or live target cells comprising: immobilizing T cells labeled with Ca2+ sensitive fluorophore on the glass bottom of a well, covered with capturing antibody or a capturing protein that bind to non-stimulatory T-cell surface receptor; adding to the well a single or multiple peptide epitopes that binds to the cell surface MHC molecules to be presented for recognition by cognate T cells; the stimulatory signal could also be delivered by live target cells that display peptide epitope(s); wherein the recognition of stimulatory of pMHC by the peptide specific T cells leads to increase of intracellular Ca2+ level and fluorescence intensity in the responding T cells, which is then identified after the subtracting fluorescence intensity for every T cell before and after the addition of the peptide antigens; scoring each responding T cell into a category according to three categories including: a rapid and sustained T-cell response, an oscillatory response, or a delayed and oscillatory response; and measuring changes in number of an individual T cells with increased intracellular fluorescence as function of time provides the kinetic curve of the TCR-mediated Ca2+ signaling.

A method for enhancing the immunogenicity of protein / peptide antigens, which comprises conjugating the protein / peptide antigen with a sugar to form a glyco-protein / peptide antigen conjugate, whose immunogenicity is enhanced compared to the unconjugated protein / peptide antigen. Specifically, it involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof, with a polysaccharide, especially the capsular polysaccharide of Streptococcus pneumoniae. The conjugate with enhanced immunogenicity can be used for preventing or treating diseases caused by pathogens, especially diseases caused by coronaviruses.

The invention relates to antibodies against extracellular epitopes of human Transient Receptor Potential Vanilloid 6 (TRPV6) channel protein, in particular antibodies which modulate TRPV6 channel activity on the plasma membrane and thereby trigger apoptosis of cancer cells expressing TRPV6. The invention relates also to the use of said antibodies for the diagnosis, prognosis and treatment of diseases involving TRPV6 channels, in particular diseases associated with TRPV6-expression such as cancers. The invention further relates to peptide antigens from human TRPV6 protein useful for the production of said antibodies.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also referred to as MHC class Ib molecules) in combination with peptide antigens for the treatment of type 1 diabetes (T1D). The invention more particularly relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods for producing such recombinant polypeptides, pharmaceutical compositions comprising same, and their use for treating type 1 diabetes (T1D).

The invention belongs to the technical field of medicines, and particularly relates to a milk acylation modified Myh6 protein and application thereof. The antigen polypeptide for identifying the heart failure marker has an amino acid sequence as shown in SEQ ID NO: 1, lysine located at the 9th site is subjected to milk acylation modification, and the heart failure marker is milk acylation modified Myh6 protein; the milk acylation modified Myh6 protein is a lysine milk acylation modified protein (Myh6-K1897) which is located at the 1897 site of a wild type Myh6 protein. The Myh6-K1897 can be used as a marker for identifying heart failure as a target spot, is a set of novel and perfect protein milk acylation molecular regulation and control system, can judge the interaction between Myh6 and Tin, and is used for treating the core and key of heart failure. The research provides a new and powerful treatment strategy for the treatment of human heart failure diseases.

The invention discloses a polypeptide-based avian reticuloendotheliosis virus indirect ELISA antibody detection method, and belongs to the technical field of biology. According to the kit, potential epitopes of REV gp90 protein are systematically screened to obtain three sections of specific polypeptide antigens for detecting the avian reticuloendotheliosis virus antibody, and a mixed product of the three sections of specific polypeptide antigens is used as a coating antigen to develop the indirect ELISA antibody detection kit for the avian reticuloendotheliosis virus. On the basis of the indirect ELISA antibody detection kit, the avian reticuloendotheliosis virus antibody detection method established by optimizing the coating concentration, the sealing condition, the serum incubation time and the like has the advantages of strong specificity, high sensitivity, good repeatability and convenience in operation; the kit can effectively and rapidly diagnose epidemic diseases caused by the avian reticuloendotheliosis virus, and is beneficial to popularization and application.

The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.

The present invention provides a novel method for identifying peptide antigens associated with non-autoimmune diseases involving T cell activation, as well as novel peptides identified thereby. The isolated peptides of the present invention can be used for the diagnosis, prevention, and / or treatment of cardiovascular diseases, more specifically heart failure (HF). The present invention also provides a pharmaceutical composition comprising at least one of the isolated peptides of the present invention and a pharmaceutically acceptable carrier, vehicle, excipient, and / or diluent. The pharmaceutical composition of the present invention is suitable for oral administration as a tolerogenic vaccine.

The embodiment of the present application provides a kind of polypeptide antigen and its preparation method and application.The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg.The polypeptide antigen in the present application has strong conformational stability, by setting up diphenyl cyclooctyne group (DBCO) on the side chain of Lys residue in polypeptide antigen, by group modification, provide the activity of click chemistry reaction with endogenous or exogenous azide compound in biological system, significantly prolong the circulating half-life of polypeptide in vivo;Through cyclic structure and group modification, the polypeptide antigen can effectively target and act on T cell, improve treatment efficiency.

Engineered filamentous bacteriophage particle are provided, and DNA extracted from such phage particles, including: (a) a filamentous bacteriophage capsid comprising a peptide antigen displayed on a surface of the capsid; and (b) a single stranded DNA molecule (ssDNA) encapsulated within the capsid, wherein the single stranded DNA molecule; wherein (i) the ssDNA comprises at least 12% unmethylated CG dinucleotides; (ii) the ssDNA comprises sequences encoding bacteriophage (A) fl-ori, (B) fl-term, and (C) packaging signal; and (iii) the ssDNA comprises less than 50% bacteriophage ssDNA.